Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232828 | 0.89 | MAPT (0.55) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL7234678 | 0.88 | MAPT (0.54) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| Lithium Ion SCHEMBL7234683 | 0.87 | MAPT (0.55) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL29800844 | 0.86 | MAPT (0.57) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL21633383 | 0.86 | MAPT (0.57) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL30208188 | 0.86 | MAPT (0.72) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL15797078 | 0.86 | MAPT (0.72) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL7242118 | 0.85 | MAPT (0.56) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL7235368 | 0.84 | MAPT (0.63) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 | |
| SCHEMBL10063610 | 0.84 | MAPT (0.59) | MAPTSMN1; SMN2ALDH1A1LMNAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | MAPT 3413/4885SMN1; SMN2 1984/4885ALDH1A1 2084/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | MAPT 4086/4885SMN1; SMN2 913/4885ALDH1A1 650/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | MAPT 4300/4885SMN1; SMN2 813/4885ALDH1A1 918/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | MAPT 3413/4885SMN1; SMN2 1984/4885ALDH1A1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.